StemCyte Biologics is the clinical development arm of StemCyte, Inc., advancing cord blood-derived cell therapies for serious diseases. The pipeline includes REGENECYTE® (FDA-licensed under US License 2280 for unrelated allogeneic hematopoietic progenitor cell transplantation) and three StemCyte-sponsored clinical trials covering Long COVID (NCT05682560), acute ischemic stroke (NCT02433509), and cerebral palsy (NCT06377982). REGENECYTE® holds FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Long COVID.
Regenerative Therapeutics
Advancing cell therapy from bench to bedside
REGENECYTE® is FDA-licensed under US License 2280. An active clinical pipeline. 27 years of stem cell science translated into patient outcomes.
FDA
FDA Biologics License
US License 2280 · Approved 2024
2,300+ transplants
Across 325+ institutions
Biologics Programs
FDA US License 2280 RMAT Designation FACT Accredited AABB Accredited 325+ Institutions
Medical information inquiries
Product information, clinical data requests, and medical affairs inquiries.
Contact Medical Affairs